THE COMPANY

CannBioRex is a pioneer in the field of synthetic non-psychoactive cannabinoids, and the result of a twenty-year collaboration between Professor Sir Marc Feldmann and Professor Raphael Mechoulam, who is a leading expert in cannabis chemistry and successfully identified THC, CBD, and endocannabinoids. Teams at the Kennedy Institute of Rheumatology at the University of Oxford, and the Hebrew University of Jerusalem, are working in tandem towards these goals.

Despite roughly 3,000 pharmaceutical and biotechnology companies existing globally, there are only a handful of companies actively developing synthetic cannabinoids for human and veterinary health. Presently, most of the focus is in pain management, multiple sclerosis and epileptic seizure disorders.

There are still significant unmet needs for orally available, relatively safe anti-inflammatory drugs, especially with some analgesic properties. Cannabinoids fulfil these properties, especially those which do not, like cannabidiol, have psychotropic properties. CannBioRex plans to apply the complementary scientific skills of teams based at the Kennedy Institute at Oxford (Prof Sir Marc Feldmann, Prof Richard Williams and Prof Chas Bountra) and the Hebrew University of Jerusalem (Prof Raphael Mechoulam and Prof Ruth Gallily) to develop novel synthetic orally available and patentable medications to primarily treat arthritis and pain. Post-company development will focus on encompassing further indications such as multiple sclerosis, diabetes, obesity and fatty liver. There is a long track record of expertise in these centres in studying these diseases and in generating and testing therapeutics especially cannabinoids. The team is able to lead the research from the generation purification and manufacture of new cannabinoids (Prof Raphael Mechoulam), evaluating and prioritizing them (Prof Ruth Gallily), testing them in animal models (Prof Richard Williams) and planning their clinical evaluation inpatients (Prof Marc Feldmann and Prof Chas Bountra). CannBioRex’s team has worked together from the late ‘90s, and has published a series of papers in this field.

Cannabinoid receptors are prevalent in the cardiovascular system, bone marrow, immune organs and the lymph system. In this way they can act as possible mediators to a variety of inflammatory conditions such as immune inflammation (MS and arthritis), brain inflammation (migraines, epilepsy, autism) and general muscle inflammation.7 Resultantly, cannabinoids are an important way in which the human body can maintain balance and regulate negative medical conditions occurring across numerous organs and systems. CBD is an indispensable catalyst for optimal health through homeostasis; balance in the body.

Both the endocannabinoid system and the two naturally-occurring cannabinoids in the human body (2AG and Anandamide) were discovered by CannBioRex’s co-founder Prof Raph Mechoulam’s extensive research across 50 years of isolating and synthesizing cannabis related compounds.

The Company holds worldwide exclusive licenses for three patents from Yissum Research Development Company of Hebrew University. These licenses are the basis of Prof Raphael Mechoulam (Co-Founder of the Company), Prof Ruth Gallily and their team at The Hebrew University of Jerusalem. These patents are based on novel synthetic cannabinoids for uses in the Company’s target indications.

THE SCIENCE

The initial focus of the research will be on the development of safe and well-tolerated compounds with analgesic and immunoregulatory activity and with the capacity to synergise with current therapies, such as TNFα inhibitors, which primarily target downstream inflammatory processes. cannabinoids mediate their diverse effects principally by binding to one of two cell membrane receptors, CB1 and CB2, which belong to the G protein-coupled receptor superfamily. Most of the psychotropic effects of cannabinoids are mediated by CB1 receptors therefore our research will focus on selective CB2 receptor agonists, which are widely expressed by cells of the immune system.

THE ADVANTAGE

The development and clinical study of synthetic cannabinoids will have several key advantages over medical marijuana.

  • Use of a pure compound vs. a mixture of compounds.
  • Ability to test and control dosing, which in turn controls efficacy and side effect levels.
  • Create a reproducible product.
  • Ability to engineer a product to prevent or aid passage across blood-brain barrier, whichever is preferred.
  • Ability to engineer novel synthetic versions to control binding preferences to different cannabinoid receptor subtypes.
  • Control agonist or antagonist effects of receptor binding.
  • Modify half-life of the drug in the body.
  • Create pro-drug forms that are only activated in specified tissues, thereby potentially reducing side effects.
1. Compound synthesis
2. Preliminary characterisation
3. T cell differentation assay
4. AIA model & assessment of analgesia
5. CIA model
6. MoA & biomarker analyses

TARGET INDICATIONS

The market for treating osteoarthritis was worth $7.96B USD in 2017, and is expected to rise to $11.62B USD in 2025 at a CAGR of 4.8%. Sales would dramatically augment with effective drugs.

The market for treating chronic pain was worth $69.3B USD in 2017, and is expected to rise to $106.99B USD in 2024 at a CAGR of 6.4%.